🇺🇸 Glecaprevir and Pibrentasvir in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 6
Most-reported reactions
- Acute Respiratory Failure — 2 reports (33.33%)
- Aspiration — 1 report (16.67%)
- Hepatitis C — 1 report (16.67%)
- Off Label Use — 1 report (16.67%)
- Treatment Failure — 1 report (16.67%)
Other Virology/Hepatology approved in United States
Frequently asked questions
Is Glecaprevir and Pibrentasvir approved in United States?
Glecaprevir and Pibrentasvir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Glecaprevir and Pibrentasvir in United States?
Massachusetts General Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.